Replies to post #189110 on Enzolytics Inc (ENZC)

[Dyno89]

I think following and then being in this other low float Nasdaq small bio has changed my outlook on ENZC for the negative.

Their share structure is insanely low, like 25 mil or under, the o/s is only about 8 mil and they have stage 2 trials completed in Europe and they are starting FDA clinicals in the states here. Yet they are trading well under a dollar after being above $10 a year ago.

I think seeing this other one play out real time for a year on a Nasdaq small bio opened my eyes to where this SAGA thing is likely headed short term after the dividend pays out and everything is completed.

If people are planning to wait it out for years under SAGA, then that’s one thing. Obviously anything can happen long term. But being three years into this so far, I never expected that we’d be entering a spac deal where we may be waiting another year or more just to be entering a valid clinical trial in either EU or other. I thought we’d have been way further down the road than we are currently, especially after talk from Chandra like “4 revenue generating products to market in 2022”.

That’s what crossed the line for me to where I stand now on this. We’re in 4th quarter 2023 after statements years ago like the one above and we still haven’t seen a SINGLE revenue generating product to market.